Skip to main content

Table 3 Distribution of changes in perceived risk from baseline to follow-up, stratified by cancer, genetic result, and follow-up time

From: The impact of direct-to-consumer personal genomic testing on perceived risk of breast, prostate, colorectal, and lung cancer: findings from the PGen study

  Breast Prostate Colorectal Lung
Genetic risk result Average Elevated Average Elevated Average Elevated Average Elevated
2-week follow-up
Frequency, n (%) 514 (89.2) 62 (10.8) 278 (78.5) 76 (21.5) 728 (75.1) 241 (24.9) 781 (80.8) 185 (19.2)
Unit change in perceived risk (%)
 −4 0.0 0.0 0.0 0.0 0.1 0.0 0.1 0.0
 −3 0.6 0.0 1.4 0.0 0.7 0.4 0.5 0.0
 −2 6.8 6.5 5.0 1.3 3.6 0.8 2.7 1.6
 −1 23.7 6.5 26.6 14.5 22.7 11.6 19.1 11.4
 0 51.6 37.1 51.1 25.0 50.0 38.2 47.0 37.3
 + 1 14.0 35.5 14.0 35.5 19.2 35.7 24.2 31.9
 + 2 3.3 14.5 1.4 14.5 3.7 9.5 5.9 12.4
 + 3 0.0 6.5 0.4 7.9 0.0 3.7 0.5 5.4
 + 4 0.0 0.0 0.0 1.3 0.0 0.0 0.0 0.0
6-month follow-up         
Frequency, n (%) 511 (90.4) 54 (9.6) 266 (77.6) 77 (22.4) 717 (75.7) 230 (24.3) 773 (81.8) 172 (18.2)
Unit change in perceived risk (%)
 −4 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0
 −3 0.6 1.9 0.8 0.0 0.1 0.0 0.7 0.0
 −2 6.7 0.0 4.9 5.2 4.6 1.7 2.7 1.7
 −1 23.1 18.5 26.3 10.4 21.5 15.7 18.4 12.8
 0 50.9 33.3 51.5 32.5 52.4 40.9 48.0 41.3
 +1 13.9 27.8 14.7 33.8 16.9 30.0 22.9 27.9
 +2 4.5 13.0 1.9 10.4 4.2 9.6 6.3 10.5
 +3 0.4 1.9 0.0 5.2 0.1 2.2 0.8 5.8
 +4 0.0 3.7 0.0 2.6 0.1 0.0 0.1 0.0